NVCR vs WVE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.
WVE exhibits severe financial distress from a deterministic standpoint, highlighted by a critical Piotroski F-Score of 1/9. While the company maintains a strong liquidity position with a current ratio of 6.47 and negligible debt, these are offset by a catastrophic 79.4% decline in year-over-year revenue and an operating margin of -327.44%. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling by the CEO and CFO, alongside a recent 37% price collapse. The valuation is purely speculative, as evidenced by a Price/Sales ratio of 32.21 in the face of shrinking revenues.
Compare Another Pair
Related Comparisons
NVCR vs WVE: Head-to-Head Comparison
This page compares NovoCure Limited (NVCR) and Wave Life Sciences Ltd. (WVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.